Experimental and new investigational drugs for the treatment of uterine fibroids

References

• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–686. doi: 10.1093/humupd/dmw023
   PubMed Web of Science ®Google Scholar
• Lagana AS, Vergara D, Favilli A, et al. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease. Arch Gynecol Obstet. 2017;296(5):855–867. doi: 10.1007/s00404-017-4515-5
   PubMed Web of Science ®Google Scholar
• Botía, CP, Camarasa, SC, Baixauli, FR, et al. Uterine fibroids: understanding their origins to better understand their future treatments. 2017.
   Google Scholar
• Perez-Lopez FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106–116. doi: 10.1016/j.maturitas.2014.06.002
   PubMed Web of Science ®Google Scholar
• Ikhena DE, Bulun SE. Literature review on the role of uterine fibroids in endometrial function. Reprod Sci. 2018;25(5):635–643. doi: 10.1177/1933719117725827
   PubMed Web of Science ®Google Scholar
• Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015;2015(3). CD010854. doi: 10.1002/14651858.CD010854.pub2
   PubMedGoogle Scholar
• Bristot M, Grande AJ, Laura M, et al. Efficacy of ulipristal acetate for uterine fibroids an updated meta-analysis. 2021.
   Google Scholar
• Vitale SG, Ferrero S, Caruso S, et al. Ulipristal acetate before hysteroscopic myomectomy: a systematic review. Obstet Gynecol Surv. 2020;75(2):127–135. doi: 10.1097/OGX.0000000000000764
   PubMed Web of Science ®Google Scholar
• Ferrero S, Scala C, Vellone VG, et al. Preoperative treatment with ulipristal acetate before outpatient hysteroscopic myomectomy. Gynecol Obstet Invest. 2020;85(2):178–183. doi: 10.1159/000505604
   PubMed Web of Science ®Google Scholar
• Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018;14(1):107–116. doi: 10.1080/17425255.2018.1417389
   PubMed Web of Science ®Google Scholar
• Dababou S, Garzon S, Laganà AS, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021;30(9):903–911. doi: 10.1080/13543784.2021.1957830
   PubMed Web of Science ®Google Scholar
• Markham A. Relugolix: first global approval. Drugs. 2019;79(6):675–679. doi: 10.1007/s40265-019-01105-0
   PubMed Web of Science ®Google Scholar
• Lamb YN. Elagolix: first global approval. Drugs. 2018;78(14):1501–1508. doi: 10.1007/s40265-018-0977-4
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis? Int J Mol Sci. 2021;22(21):11342. doi: 10.3390/ijms222111342
   PubMed Web of Science ®Google Scholar
• Evangelisti G, Barra F, Perrone U, et al. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids. Expert Opin Drug Metab Toxicol. 2022;18(7–8):441–457. doi: 10.1080/17425255.2022.2113381
   PubMed Web of Science ®Google Scholar
• Tafi E, Scala C, Leone Roberti Maggiore U, et al. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf. 2015;14(6):965–977. doi: 10.1517/14740338.2015.1021773
   PubMed Web of Science ®Google Scholar
• Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90(2):953–961. doi: 10.1210/jc.2004-1569
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104(2):426–34 e1. doi: 10.1016/j.fertnstert.2015.04.025
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14(3):181–191. doi: 10.1093/molehr/gan004
   PubMed Web of Science ®Google Scholar
• Shin SJ, Kim J, Lee S, et al. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. Int J Mol Med. 2018;42(4):1857–1864. doi: 10.3892/ijmm.2018.3779
   PubMed Web of Science ®Google Scholar
• Cox J, Malik M, Britten J, et al. Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial. Reprod Sci. 2018;25(2):198–206. doi: 10.1177/1933719117728802
   PubMed Web of Science ®Google Scholar
• Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther. 2012;29(8):655–663. doi: 10.1007/s12325-012-0042-8
   PubMed Web of Science ®Google Scholar
• Powell M, Dutta D. Esmya((R)) and the PEARL studies: A review. Womens Health. 2016;12(6):544–548. doi: 10.1177/1745505717692591
   Google Scholar
• Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. Eur J Obstet Gynecol Reprod Biol. 2017;208:91–96. doi: 10.1016/j.ejogrb.2016.11.003
   PubMed Web of Science ®Google Scholar
• Lukes AS, Soper D, Harrington A, et al. Health-related quality of life with ulipristal acetate for treatment of Uterine Leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133(5):869–878. doi: 10.1097/AOG.0000000000003211
   PubMed Web of Science ®Google Scholar
• Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018;14(9):887–889. doi: 10.1080/17425255.2018.1506766
   PubMed Web of Science ®Google Scholar
• Bradley LD, Singh SS, Simon J, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril. 2019;111(2):240–248. doi: 10.1016/j.fertnstert.2018.10.012
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Heikinheimo O, Zatik J, et al. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol. 2020;252:7–14. doi: 10.1016/j.ejogrb.2020.05.043
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Zhou YF, Faustmann T, et al. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F&S Science. 2023;4(4):317–326. doi: 10.1016/j.xfss.2023.06.003
   PubMedGoogle Scholar
• Schutt B, Kaiser A, Schultze-Mosgau MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016;31(8):1703–1712. doi: 10.1093/humrep/dew140
   PubMed Web of Science ®Google Scholar
• Błaszczak-Świątkiewicz K, Krupa A, Mnich E, et al. Next step in the development of mesoprogestins: the preclinical profile of EC313. Front Endocrinol (Lausanne). 2023;14:1201547. doi: 10.3389/fendo.2023.1201547
   PubMed Web of Science ®Google Scholar
• Nair HB, Santhamma B, Krishnegowda NK, et al. Effects of combination of estradiol with selective progesterone receptor modulators (SPRMs) on human breast cancer cells in vitro and in vivo. PLOS ONE. 2016;11(3):e0151182. doi: 10.1371/journal.pone.0151182
   PubMed Web of Science ®Google Scholar
• Nair HB, Santhamma B, Dileep KV, et al. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model. Sci Rep. 2019;9(1):17279. doi: 10.1038/s41598-019-53467-w
   PubMedGoogle Scholar
• Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health. 2015;11(1):19–28. doi: 10.2217/WHE.14.68
   Google Scholar
• Reichman D, Rosenwaks Z. GnRH antagonist-based protocols for in vitro fertilization. Methods Mol Biol. 2014;1154:289–304.
   PubMedGoogle Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019;55(8):503–512. doi: 10.1358/dot.2019.55.8.3020179
   PubMed Web of Science ®Google Scholar
• Islam MS, Parish M, Brennan JT, et al. Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids. Sci Rep. 2023;13(1):8492. doi: 10.1038/s41598-023-35212-6
   PubMed Web of Science ®Google Scholar
• Sriram N, Kalayarasan S, Manikandan R, et al. Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF-beta1 signalling. Clin Exp Pharmacol Physiol. 2015;42(8):849–859. doi: 10.1111/1440-1681.12428
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol. 2007;21(1):57–65. doi: 10.1016/j.bpobgyn.2006.08.002
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019;55(4):237–246. doi: 10.1358/dot.2019.55.4.2930713
   PubMed Web of Science ®Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–745. doi: 10.1016/0002-9378(92)91706-G
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–340. doi: 10.1056/NEJMoa1904351
   PubMed Web of Science ®Google Scholar
• Simon JA, Al-Hendy A, Archer DF, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and Uterine Leiomyomas. Obstet & Gynecol. 2020;135(6):1313–1326. doi: 10.1097/AOG.0000000000003869
   PubMed Web of Science ®Google Scholar
• Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and Uterine Leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132(5):1252–1264. doi: 10.1097/AOG.0000000000002933
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–642. doi: 10.1056/NEJMoa2008283
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140(6):920–930. doi: 10.1097/AOG.0000000000004988
   PubMed Web of Science ®Google Scholar
• Zhang D, Rajaratnam V, Al-Hendy O, et al. Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecol Obstet Invest. 2014;78(2):109–118. doi: 10.1159/000363410
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023;229(6):e662.1–e662.25. doi: 10.1016/j.ajog.2023.08.030
   Web of Science ®Google Scholar
• Keam SJ. Linzagolix: first approval. Drugs. 2022;82(12):1317–1325. doi: 10.1007/s40265-022-01753-9
   PubMed Web of Science ®Google Scholar
• ObsEvaSA. NCT03070899 - a Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women (PRIMROSE 1). clinicaltrialsgov. 2020.
   Google Scholar
• ObsEvaSA. NCT03070951 - a Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women (PRIMROSE 2). clinicaltrialsgov. 2021.
   Google Scholar
• Pohl O, Marchand L, Bell D, et al. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020;27(4):988–995. doi: 10.1007/s43032-020-00172-z
   PubMed Web of Science ®Google Scholar
• Pohl O, Marchand L, Fawkes N, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with Estradiol/Norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab. 2018;103(2):497–504. doi: 10.1210/jc.2017-01875
   PubMed Web of Science ®Google Scholar
• Evangelisti G, Ferrero S, Barra F. Linzagolix choline. Gonadotropin-releasing hormone, (GnRH) receptor antagonist, Treatment of uterine fibroids, treatment of endometriosis. Drugs Future. 2021;46(11):871. doi: 10.1358/dof.2021.46.11.3331001
   Google Scholar
• Bradley LD, Marsh EE, Garner E. Linzagolix may address the long-term treatment needs of women with uterine fibroids (UF) who have contraindications to hormonal add-back therapy (ABT): results from two phase 3 randomized clinical trials. Fertil Sterility. 2020;114(3):e527. doi: 10.1016/j.fertnstert.2020.09.017
   Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Fertil Steril. 2020;114(4):739–741. doi: 10.1016/j.fertnstert.2020.07.028
   PubMed Web of Science ®Google Scholar
• Stewart EA, Taylor HS, Taylor RN, et al. Efficacy and safety of linzagolix (LGX) for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids (UF): results from two phase 3 randomized clinical trials. Fertil Sterility. 2020;114(3):e527. doi: 10.1016/j.fertnstert.2020.09.016
   Web of Science ®Google Scholar
• ObsEva. Q3 report 2021 2021 [ Available from: https://www.obseva.com/wp-content/uploads/2021/11/ObsEva-Q3-2021-Report.pdf.
   Google Scholar
• EMA. Linzagolix: EU summary of product characteristics. 2022. [ Available from: https://ec.europa.eu/health/documents/community-register/html/h1606.htm.
   Google Scholar
• Muneyyirci-Delale O, Archer DF, Owens CD, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep. 2021;2(3):338–346. doi: 10.1016/j.xfre.2021.05.004
   PubMedGoogle Scholar
• Taylor HS, Donnez J, Bestel E, et al. Post-treatment efficacy and Safety Follow-up in women with uterine fibroids treated for 52 weeks with linzagolix [A108]. Obstet & Gynecol. 2022;139(1):31S–32S. doi: 10.1097/01.AOG.0000826752.16466.97
   PubMedGoogle Scholar
• Kim SM, Yoo T, Lee SY, et al. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis. Life Sci. 2015;139:166–174. doi: 10.1016/j.lfs.2015.08.016
   PubMed Web of Science ®Google Scholar
• Han S, Cho Y-S, Yoon S-K, et al. First-in-Human, double-blind, randomized controlled trial of an oral dose of GnRH antagonist TU2670 in healthy women. J Clin Endocrinol Metab. 2020;106(3):e1111–e20. doi: 10.1210/clinem/dgaa939
   Web of Science ®Google Scholar
• Xu Y, Hu W, Li J, et al. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women. Front Pharmacol. 2022;13:1027648. doi: 10.3389/fphar.2022.1027648
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Y, Xu B, et al. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, a Non-peptide GnRH antagonist in premenopausal women with Endometriosis: a randomized, double-blind, placebo-controlled phase 1 study. Clin Pharmacokinet. 2023;62(12):1739–1748. doi: 10.1007/s40262-023-01315-6
   PubMed Web of Science ®Google Scholar
• Malik M, Britten J, Borahay M, et al. Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. Fertil Steril. 2018;110(7):1398–407.e1. doi: 10.1016/j.fertnstert.2018.07.024
   PubMed Web of Science ®Google Scholar
• Borahay MA, Fang X, Baillargeon JG, et al. Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study. Am J Obstet Gynecol. 2016;215(6):.e750.1–.e.8. doi: 10.1016/j.ajog.2016.06.036
   Web of Science ®Google Scholar
• Ciebiera M, Wlodarczyk M, Ciebiera M, et al. Vitamin D and uterine fibroids—review of the literature and novel concepts. Int J Mol Sci. 2018;19(7):2051. doi: 10.3390/ijms19072051
   PubMed Web of Science ®Google Scholar
• Ciavattini A, Delli Carpini G, Serri M, et al. Hypovitaminosis D and “small burden” uterine fibroids: Opportunity for a vitamin D supplementation. Medicine (Baltimore). 2016;95(52):e5698. doi: 10.1097/MD.0000000000005698
   PubMed Web of Science ®Google Scholar
• Hajhashemi M, Ansari M, Haghollahi F, et al. The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency. Caspian J Intern Med. 2019;10(2):125–131. doi: 10.22088/cjim.10.2.125
   PubMed Web of Science ®Google Scholar
• Vahdat M, Allahqoli L, Mirzaei H, et al. The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study. Complement Ther Clin Pract. 2022;46:101536. doi: 10.1016/j.ctcp.2022.101536
   PubMed Web of Science ®Google Scholar
• He J, Xu L, Yang L, et al. Epigallocatechin gallate Is the most effective catechin against antioxidant stress via hydrogen peroxide and radical scavenging activity. Med Sci Monit. 2018;24:8198–8206. doi: 10.12659/MSM.911175
   PubMed Web of Science ®Google Scholar
• Zhang D, Al-Hendy M, Richard-Davis G, et al. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010;94(5):1887–1893. doi: 10.1016/j.fertnstert.2009.08.065
   PubMed Web of Science ®Google Scholar
• Ferrari E, Bettuzzi S, Naponelli V. The potential of Epigallocatechin Gallate (EGCG) in targeting autophagy for cancer treatment: a narrative review. Int J Mol Sci. 2022;23(11):6075. doi: 10.3390/ijms23116075
   PubMed Web of Science ®Google Scholar
• Roshdy E, Rajaratnam V, Maitra S, et al. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health. 2013;5:477–486. doi: 10.2147/IJWH.S41021
   PubMedGoogle Scholar
• Biro R, Richter R, Ortiz M, et al. Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study. Arch Gynecol Obstet. 2021;303(5):1235–1243. doi: 10.1007/s00404-020-05907-6
   PubMed Web of Science ®Google Scholar
• Siblini H, Al-Hendy A, Segars J, et al. Assessing the hepatic safety of Epigallocatechin Gallate (EGCG) in reproductive-aged women. Nutrients. 2023;15(2):320. doi: 10.3390/nu15020320
   PubMed Web of Science ®Google Scholar
• Porcaro G, Santamaria A, Giordano D, et al. Vitamin D plus epigallocatechin gallate: a novel promising approach for uterine myomas. Eur Rev Med Pharmacol Sci. 2020;24(6):3344–3351. doi: 10.26355/eurrev_202003_20702
   PubMed Web of Science ®Google Scholar
• Miriello D, Galanti F, Cignini P, et al. Uterine fibroids treatment: do we have new valid alternative? Experiencing the combination of vitamin D plus epigallocatechin gallate in childbearing age affected women. Eur Rev Med Pharmacol Sci. 2021;25(7):2843–2851. doi: 10.26355/eurrev_202104_25537
   PubMed Web of Science ®Google Scholar
• Grandi G, Del Savio MC, Melotti C, et al. Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study. Gynecol Endocrinol. 2022;38(1):63–67. doi: 10.1080/09513590.2021.1991909
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ulipristal acetate for uterine fibroids: EMA recommends restricting use. 2021 [ Available from: https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids_en.pdf.
   Google Scholar
• Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. Expert Opin Pharmacother. 2020;21(12):1419–1430. doi: 10.1080/14656566.2020.1755254
   PubMed Web of Science ®Google Scholar
• Food, Administration D. Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) prescribing information. 2020.
   Google Scholar
• Evangelisti G, Ferrero S, Barra F. Linzagolix choline. Gonadotropin-releasing hormone,(GnRH) receptor antagonist, Treatment of uterine fibroids, treatment of endometriosis. Drugs Of The Future. 2021;46(11):871. doi: 10.1358/dof.2021.46.11.3331001
   Google Scholar
• Ciebiera M, Meczekalski B, Lukaszuk K, et al. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies. Gynecol Endocrinol. 2019;35(6):473–477. doi: 10.1080/09513590.2018.1550062
   PubMed Web of Science ®Google Scholar
• Ali M, Shahin SM, Sabri NA, et al. 1,25 Dihydroxyvitamin D3 Enhances the antifibroid effects of ulipristal acetate in human uterine fibroids. Reprod Sci. 2019;26(6):812–828. doi: 10.1177/1933719118812720
   PubMed Web of Science ®Google Scholar
• Islam MS, Afrin S, Singh B, et al. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. Clin Transl Med. 2021;11(7):e475. doi: 10.1002/ctm2.475
   PubMed Web of Science ®Google Scholar